Abstract
These findings indicate that brain metabolism as assessed by FDG PET during mental rest is a sensitive marker of disease progression in Alzheimer's disease over a 1-year period. These findings also support the feasibility of using FDG PET as an outcome measure to test the ability of treatments to attenuate the progression of Alzheimer's disease.
Keywords
DementiaAlzheimer's diseasePositron emission tomographyMedicineInternal medicineDiseaseFluorodeoxyglucoseLongitudinal studyCarbohydrate metabolismNuclear medicinePathology
Affiliated Institutions
Related Publications
Positron emission tomography and magnetic resonance imaging in the diagnosis and prediction of dementia
Abstract Background The diagnosis of dementia, along with the prediction of who will develop dementia, has been assisted by the development of the brain imaging techniques of ma...
High Performance of <sup>18</sup>F-Fluorodeoxyglucose Positron Emission Tomography and Contrast-Enhanced CT in a Rapid Outpatient Diagnostic Program for Patients with Suspected Lung Cancer
<b><i>Background:</i></b> The diagnostic evaluation of patients presenting with possible lung cancer is often complex and time consuming. A rapid outpati...
The Fluorodeoxyglucose 18F Scan in Alzheimer's Disease and Multi-infarct Dementia
• Patients with Alzheimer's disease and multi-infarct dementia were studied with scans using fluorodeoxyglucose tagged with fluorine 18. The rates of glucose metabolism were cal...
Noninvasive functional brain mapping by change-distribution analysis of averaged PET images of H215O tissue activity.
Change-distribution analysis and intersubject averaging of subtracted positron emission tomography (PET) images are new techniques for detecting, localizing, and quantifying sta...
Lecanemab in Early Alzheimer’s Disease
Lecanemab reduced markers of amyloid in early Alzheimer's disease and resulted in moderately less decline on measures of cognition and function than placebo at 18 months but was...
Publication Info
- Year
- 2002
- Type
- article
- Volume
- 159
- Issue
- 5
- Pages
- 738-745
- Citations
- 518
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
518
OpenAlex
Cite This
Gene E. Alexander,
Kewei Chen,
Pietro Pietrini
et al.
(2002).
Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer’s Disease Treatment Studies.
American Journal of Psychiatry
, 159
(5)
, 738-745.
https://doi.org/10.1176/appi.ajp.159.5.738
Identifiers
- DOI
- 10.1176/appi.ajp.159.5.738